<DOC>
	<DOCNO>NCT01784562</DOCNO>
	<brief_summary>The aim study ass safety , tolerability clinical effect different dos riociguat patient inoperable Chronic Thromboembolic Pulmonary Hypertension ( CTEPH ) satisfactorily treat participate CTEPH trial . In US study run Expanded Access program 21 CFR 312.320 .</brief_summary>
	<brief_title>Riociguat Patients With Chronic Thromboembolic Pulmonary Hypertension ( CTEPH )</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Male female patient CTEPH either inoperable persistent recurrent PH surgery All type pulmonary hypertension Dana Point Classification Group 4 Operable patient list PEA ( Pulmonary Endarterectomy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Chronic thromboembolic pulmonary hypertension</keyword>
</DOC>